ICON Reports Fourth Quarter and Full Year 2016 Results

Highlights

· Quarter 4 gross business wins of $605 million, a gross book to bill of 1.39. Net business wins of $434 million, a net book to bill of 1.0. Full year gross business wins of $2.3 billion, a gross book to bill of 1.39, net business wins of $1.9 billion, a net book to bill of 1.13.

· Quarter 4 net revenue increased 7.9% year on year to $435 million. Full year 2016 net revenue increased 5.8% to $1,666 million.

· Quarter 4 income from operations up 12.3% year on year to $84.6 million or 19.5% of revenue. Full year 2016 income from operations up 13.6% to $319.9 million or 19.2% of revenue.

· Earnings per share for quarter 4 of $1.33, up 19.8% year on year. Earnings per share on a pro forma full year 2016 basis were $4.77, up 19.8% on 2015.

· Full year 2017 revenue guidance reaffirmed in the range of $1,700 – $1,750 million, representing growth of 2.0 – 5.0%. Earnings per share guidance in the range of $5.00 – $5.20 representing an increase of 4.8 – 9.0%.

Full consolidated income statements and balance sheet data can be viewed here.

· ICON acquired ClinicalRM to extend its presence in the market for government sponsored research and enhance its capabilities in vaccines and infectious disease

· ICON was selected by Genomics England to support the world’s largest genome sequencing project for cancer and rare diseases. The 100,000 Genomes Project will accelerate the development of more targeted and personalised medicines for cancers and rare diseases.

·  ICON won 3 industry awards in 2016  – it was awarded Ireland’s top company; Pharma Contract Services Company of the Year; and Clinical Research Team of the Year.

·  ICON renewed its partnership with Pfizer, whereby ICON will continue to provideexpertise in the planning, execution, management and conduct of Pfizer’s clinical trials.

Read More

Almac Diagnostics Appoints Dr Leeona Galligan as Vice President UK Operations

Craigavon, N.I., 15 February 2017 – Almac Diagnostics, the global personalised medicine company, focusing on the discovery, development and commercialisation of complex diagnostic and companion diagnostic tests, has announced the appointment of Dr. Leeona Galligan (PhD, FRCPath) to the position of Vice President, UK Operations.

In her new role, Dr Galligan will be responsible for all UK based operations including commercial biomarker discovery, CLIA/FDA compliant analytical validation, downstream clinical testing, manufacturing and shipping of clinical specimen and release of controls and reagents for registrational clinical trials. In addition, she will continue to serve as a valuable member of the Almac Diagnostics’ Executive team helping to define and implement its global business strategy.

Read More

One of Northern Ireland’s most successful companies is opening a new plant in the Republic of Ireland, creating 100 jobs, to maintain EU access after Brexit.

Pharmaceutical firm Almac Group, which has its headquarters in Craigavon, Co Armagh, said it was making a multimillion-pound investment in its new facility at Dundalk, Co Louth, just south of the border.

The move “provides continued presence within the European Union in the long-term”, the company announced in a statement.
Read More

Almac Group Launches Almac Clinical University

A first-in-industry, web-based training & education platform designed to enhance, educate, and strengthen connections with industry professionals and valued clients across the globe

SOUDERTON, PA (PRWEB) JANUARY 09, 2017: Almac Clinical Technologies, part of the Almac Group, the world’s largest privately-held contract pharmaceutical development and manufacturing organisation, today announced the launch of Almac Clinical University, a first-in-industry web-based training and educational platform.

The innovative platform is designed specifically for Clinical Development professionals and offers a vast library of educational resources for industry best-practices and current challenges, along with exclusive custom-built training programs for existing clients to enhance their partnership with Almac.

“With the launch of Almac Clinical University, there’s now a unique place for our industry to explore and exchange knowledge in a free-flowing format” – George Tiger, VP Global Business Development

To read more, please click HERE.